All News
Filter News
Found 927 articles
-
Galapagos appoints Paul Stoffels as Chief Executive Officer
1/26/2022
Galapagos NV (Euronext & NASDAQ: GLPG) is pleased to announce the appointment of Dr. Paul Stoffelsas Chief Executive Officer (CEO),effective April 1, 2022.
-
JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN
1/18/2022
Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for Jyseleca®(filgotinib 200mg tablets), as a new treatment for ulcerative colitis (UC) for Great Britain.
-
PureTech’s LYT-100 (Deupirfenidone) Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to Pirfenidone
1/6/2022
PureTech Health plc announced results from a randomized, double-blind crossover study in healthy older adults demonstrating that approximately 50% fewer subjects treated with PureTech’s LYT-100 experienced gastrointestinal -related adverse events compared to subjects treated with pirfenidone.
-
Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference
1/6/2022
Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the40th Annual J.P. Morgan Healthcare Conference on January 10-13, 2022.
-
Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
12/23/2021
Pharnext SA announces the appointment of Dr. Elisabeth Svanberg MD, PhD to succeed Michel de Rosen as Chairman of the Board of Directors effective January 1st, 2022.
-
Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP
12/21/2021
Agomab Therapeutics NV announced the expansion of its team with two key hires: Reginald Brys will join as Head of Research and Maria Nichol will become Head of Intellectual Property.
-
Ryvu announces option to license inflammation program exercised by Galapagos NV
12/14/2021
Ryvu Therapeutics S.A. announced that the pre-agreed criteria in the Option, License and Research Collaboration Agreement, announced between Ryvu and Galapagos on April 16, 2020, have been achieved and Galapagos has exercised its exclusive option for the program.
-
Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
11/22/2021
Galapagos NV (Euronext & NASDAQ: GLPG) announces completion of recruitment in the MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with autosomal dominant polycystic kidney disease (ADPKD).
-
Biopharma and life sciences companies from across the globe provide updates. Belgium-based Galapagos NV won European approval for Jyseleca for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
-
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
11/15/2021
Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the European Commission has granted marketing authorization for Jyseleca®(filgotinib 200mg tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
-
Galapagos reports commercial and operational progress at Q3 financial results
11/4/2021
Galapagos NV is pleased to report on itscommercial launch of filgotinib in Europe.The company is moving forward with its revised R&D strategy and operational restructuring announced in May, resulting in a downward adjustment of thecash burn by €50 million.
-
InteRNA Technologies Establishes Clinical Advisory Board and Appoints New Members to Scientific Advisory Board
10/19/2021
InteRNA Technologies, a clinical-stage biotech company developing microRNA -based therapeutics with a focus on cancer, announced the establishment of a Clinical Advisory Board and the appointment of new members to its Scientific Advisory Board.
-
Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
10/4/2021
Galapagos NV (Euronext & NASDAQ: GLPG) todayannouncedresults of twopost-hoc analyses from the SELECTION and SELECTION LTEstudies, which are part of the investigational clinical program for filgotinib, forthe treatment of patients with moderately to severely activeUC.
-
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
10/4/2021
Galapagos NV announced randomization of the last patient into the multi-center, globalDIVERSITY Phase 3 study.
-
Blade Therapeutics Announces Positive Data from Preclinical Drug-Drug Interaction Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis (IPF)
9/20/2021
Blade Therapeutics, Inc. today announced positive preliminary data from a new preclinical study of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF.
-
Galapagos increases share capital through subscription right exercises - Sep 20, 2021
9/20/2021
Galapagos issued 7,600 new ordinary shares on 20 September 2021, for a total capital increase of €151,787.50.
-
GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
9/17/2021
Galapagos NV today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca
-
First-of-its-Kind, Global Data Repository for Interstitial Lung Diseases Launches Through Academic and Industry Collaborative
9/7/2021
The Open Source Imaging Consortium (OSIC) today announced the launch of its global, data-rich repository of anonymized HRCT scans and clinical information regarding interstitial lung diseases (ILDs)
-
Henceforth, all JAK-inhibiting drugs like AbbVie’s Rinvoq, Pfizer’s Xeljanz, and Lilly’s Olumiant, have been ordered to include a warning label on the medicine to be sold in the U.S.
-
As CEO, Stolpe has presided over some highs with the launch of JAK1 inhibitor Jyseleca (filgotinib) in Europe, as well as the devaluation of the company's share price by 70%.